Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG.

Trial Profile

Phase I/II Radioimmunotherapy of Non-Hodgkin's Lymphoma With Radiolabeled Humanized Immuno-LL2: Treatment With 90Y-hLL2 IgG.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Epratuzumab Y-90 (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Immunomedics
  • Most Recent Events

    • 15 Jun 2009 Results have been presented at the 56th Annual Meeting of the Society of Nuclear Medicine (2009), as reported in an Immunomedics media release. Actual patient number updated (n=64).
    • 17 Jan 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jun 2007 Interim results were presented at the 12th Congress of the European Hematology Association in June 2007 (9076809).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top